Davita (DVA) Stock News

DaVita (NYSE: DVA) will report third quarter 2025 results and host a conference call on Wednesday, October 29, 2025. Results will be released after market close the same day, and the call starts at 5:00 p.m. Eastern Time. The call will be webcast and accessible on DaVita's investor relations webpage.

Dial-in details: domestic 877-918-6630, international 517-308-9042; participants should provide the password "Earnings" and their name/company. A webcast replay will be available at investors.davita.com; there will be no telephone replay.

Operational snapshot: as of June 30, 2025, DaVita served ~283,100 patients at 3,175 outpatient dialysis centers (2,662 U.S.; 513 in 13 other countries).

DaVita (NYSE:DVA), a leading kidney care provider, celebrates 25 years of its research division DaVita Clinical Research (DCR). The research arm has conducted over 500 clinical trials across 250+ research sites, with 8,900+ participants in the last 5 years. DCR has contributed to every FDA-approved ESKD drug and published 180 manuscripts and 520 research abstracts.

Notable achievements include participation in COVID-19 vaccine trials, revising nephrology standards for anemia management, and implementing decentralized recruitment services in 2024 to increase diverse patient participation. The company currently serves 283,100 patients at 3,175 outpatient dialysis centers globally, with 2,662 centers in the US and 513 centers across 13 other countries.

DaVita Inc. (NYSE: DVA) reported its Q2 2025 financial results with consolidated revenues of $3.380 billion and operating income of $538 million. The company achieved diluted earnings per share of $2.58 and adjusted diluted EPS of $2.95.

Key highlights include $324 million in operating cash flow, issuance of $1.0 billion of 6.75% senior notes, and repurchase of 3.1 million shares at an average price of $144.00. The company experienced a cybersecurity incident resulting in $13.5 million in charges. DaVita served approximately 283,100 patients across 3,175 outpatient dialysis centers globally.

For 2025 guidance, DaVita projects adjusted operating income of $2,010-$2,160 million and adjusted diluted EPS of $10.20-$11.30.

DaVita Inc. (NYSE: DVA) has scheduled its second quarter 2025 earnings conference call for Tuesday, August 5, 2025, at 5:00 p.m. Eastern Time. The company will release its financial results after the market closes on the same day.

Investors can access the call through a webcast on DaVita's investor relations website or by dialing 877-918-6630 (US) or 517-308-9042 (International). Participants should provide the password "Earnings" when joining. A replay will be available on the company's website, but no telephone replay option will be provided.

DaVita (DVA) announced that the Center for Medicare and Medicaid Innovation (CMMI) has extended its Kidney Care Choices (KCC) Model for an additional year. The company, a leading kidney care provider, has expanded its value-based care arrangements from 11 Kidney Contracting Entities (KCEs) in 2022 to 22 KCEs currently. Recent reports show these arrangements have improved patient outcomes, including increased transplantation rates, more optimal dialysis access placement, and higher home dialysis adoption. DaVita serves approximately 282,000 patients across 3,173 outpatient dialysis centers globally, with 2,661 centers in the United States and 512 centers in 13 other countries as of March 31, 2025.

DaVita Inc. (NYSE: DVA) has successfully upsized and priced its private offering of 6.750% senior notes due 2033 from $750 million to $1 billion. The notes were priced at 100.000% of their face value, yielding a 6.750% coupon. The offering is expected to close on May 23, 2025.

The company plans to use the proceeds to repay outstanding revolving credit facility borrowings, cover related costs and fees, and if funds remain, for general corporate purposes including stock repurchases, working capital, and capital expenditures. The notes were offered exclusively to qualified institutional buyers under Rule 144A and certain non-U.S. persons under Regulation S of the Securities Act.

DaVita (NYSE: DVA) has released its 2024 Community Care report, marking significant achievements in its ESG initiatives. Key highlights include: a record 8,200+ kidney transplants, 15% of patients utilizing home dialysis, and over 40,000 participants in Kidney Smart® education programs. The company demonstrated strong teammate engagement with 84% reporting workplace belonging and 147,000+ volunteerism hours. In environmental stewardship, DaVita is on track for 100% renewable energy matching by 2025 and saved 75+ million gallons of water in 2024. The company expanded community health initiatives through its Health Tour and provided 100,000+ medically tailored meals through the Food is Medicine Coalition. Corporate governance remained strong with 90% independent board members and 99.9% compliance training completion.

DaVita Inc. (NYSE: DVA) has announced a private offering of $750 million senior notes due 2033. The company plans to use the proceeds to repay outstanding revolving credit facility borrowings and related interest, cover associated costs and fees, and if funds remain, for general corporate purposes including stock repurchases, working capital, and capital expenditures.

The notes are being offered exclusively to qualified institutional buyers under Rule 144A of the Securities Act and certain non-U.S. persons under Regulation S. The offering is not registered under the Securities Act or other jurisdictions' securities laws and cannot be sold in the United States without registration or an applicable exemption.

DaVita Inc. (DVA) reported its Q1 2025 financial results with consolidated revenues of $3.224 billion and operating income of $439 million. The company achieved diluted earnings per share of $2.00, down from $2.65 in Q1 2024. Operating cash flow was $180 million, while free cash flow was $(45) million. DaVita repurchased 3.7 million shares at an average price of $148.94 per share. The company served approximately 282,000 patients across 3,173 outpatient dialysis centers, with 2,661 centers in the U.S. and 512 internationally. Revenue per treatment increased to $400.14, up from $384.54 year-over-year. For 2025, DaVita projects adjusted operating income between $2,010-$2,160 million and adjusted diluted EPS of $10.20-$11.30.